As the respiratory syncytial virus (RSV) vaccine field grapples with a significantly reduced market size thanks to regulatory ...

Pfizer (PFE) and GSK (GSK) settle RSV vaccine patent lawsuit, dismissing the case with prejudice. REad more here.

British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that alleged Pfizer's respiratory ...

Older adults and people with certain medical conditions are more likely to receive the respiratory syncytial virus (RSV) ...

Initially allocated Rs. 20,000 crore and later extended to Rs. 22,500 crore until March 2026, the program aims to significantly reduce pollution, boost biodiversity, and foster a deeper connection ...

Abrysvo is now approved in the EU for adults aged 18 to 59 who are at increased risk of lower respiratory tract disease ...

Children aged 6 months to 12 years are the main spreaders of respiratory syncytial virus (RSV) infections within their ...

Pfizer has won European Commission expanded approval of its Abrysvo vaccine for respiratory syncytial virus, or RSV, for use in all adults. The New York drugmaker on Tuesday said the extended ...

A new brief report published in the American Journal of Infection Control (AJIC) demonstrates that ActivePure’s Advanced Photohydrolysis (AP) Technology effectively and rapidly inactivates aerosolized ...

The European Commission approved Pfizer's respiratory syncytial virus vaccine for the prevention of lower respiratory tract ...

Knowledge of respiratory syncytial virus (RSV) disease and RSV vaccine eligibility was low in this cross-sectional study of hospitalized adults. Older adults and those with certain medical conditions ...